Business ActivitiesR&D pipeline

Human Life CORD is dedicated to developing innovative solutions for challenging medical conditions. In collaboration with the Institute of Medical Science, the University of Tokyo and leading research institutions, we are conducting extensive R&D on HLC-001, a product derived from umbilical cord mesenchymal stromal cells. Our goal is to provide new treatment options for diseases where mesenchymal stromal cells have therapeutic potential.

Flow until Application for Approval

Basic research

Non-clinical studies

Phase1

Phase2

Phase3

Application for approval

Immunological and inflammatory diseases

Scheduled indication	Non-infectious pulmonary complications after hematopoietic stem cell transplantation.
Progress	Phase22022 Mar Phase 2 Start
Remarks	Phase 2 study: Case enrollment in progress

Scheduled indication	Acute graft versus host disease after hematopoietic stem cell transplantation
Progress	Phase12020 Mar Completed
Remarks	Phase 1 study: Completed (physician-initiated clinical trial by the Institute of Medical Science, the University of Tokyo, exclusive licensing of the outcomes from the University of Tokyo) An article on Phase 1 results was published in an international journal in the hematology field (July 2022).

Scheduled indication	Acute respiratory distress syndrome associated with COVID-19
Progress	Phase12022 Mar Completed
Remarks	Phase 1 study: enrollment and observation period completed

Scheduled indication	Haemophagocytic syndrome
Progress	Non-clinical studies
Remarks	Joint research with the Institute of Medical Science, the University of Tokyo is underway (application patent pending). Presentation of results at the Japan Society of Hematology (October 2020)

Scheduled indication	Acute radiation damage
Progress	Non-clinical studies
Remarks	Joint research with the Institute of Medical Science, the University of Tokyo is underway (application patent pending). Presentation of results at the Japanese Society for Regenerative Medicine (March 2020)

Scheduled indication	Progress	Remarks
Non-infectious pulmonary complications after hematopoietic stem cell transplantation.	Phase22022 Mar Phase 2 Start	Phase 2 study: Case enrollment in progress
Acute graft versus host disease after hematopoietic stem cell transplantation	Phase12020 Mar Completed	Phase 1 study: Completed (physician-initiated clinical trial by the Institute of Medical Science, the University of Tokyo, exclusive licensing of the outcomes from the University of Tokyo) An article on Phase 1 results was published in an international journal in the hematology field (July 2022).
Acute respiratory distress syndrome associated with COVID-19	Phase12022 Mar Completion of registration	Phase 1 study: enrollment and observation period completed
Haemophagocytic syndrome	Non-clinical studies	Joint research with the Institute of Medical Science, the University of Tokyo is underway (application patent pending). Presentation of results at the Japan Society of Hematology (October 2020)
Acute radiation damage	Non-clinical studies	Joint research with the Institute of Medical Science, the University of Tokyo is underway (application patent pending). Presentation of results at the Japanese Society for Regenerative Medicine (March 2020)

Age-related disease

Scheduled indication	Sarcopenia
Progress	Non-clinical studiesAnimal POC
Remarks	Joint research with Nagoya University (application patent pending) Presentation of outcomes at the Japanese Association on Sarcopenia and Frailty Conference (Completed in November 2021, scheduled for October 2022) Papers of basic research results were published in the International Journal of Stem Cell Research and Therapy (June 2022)

Scheduled indication	Progeria (Werner's syndrome)
Progress	Basic research
Remarks	Joint research is underway with the Institute of Medical Science, the University of Tokyo

Scheduled indication	Progress	Remarks
Sarcopenia	Non-clinical studiesAnimal POC	Joint research with Nagoya University (application patent pending) Presentation of outcomes at the Japanese Association on Sarcopenia and Frailty Conference (Completed in November 2021, scheduled for October 2022) Papers of basic research results were published in the International Journal of Stem Cell Research and Therapy (June 2022)
Progeria (Werner's syndrome)	Non-clinical studies	Joint research is underway with the Institute of Medical Science, the University of Tokyo

Noninfectious pulmonary complications (NIPCs) after hematopoietic stem-cell transplantation

Noninfectious pulmonary complications (NIPCs) after hematopoietic stem-cell transplantation are disorders such as pneumonitis caused by factors other than infection after transplantation. Idiopathic pneumonia syndrome (IPS) is a common NIPC. IPS often begins early after transplantation, when the walls of the alveoli in the lungs become inflamed or damaged, the walls become thicker (fibrotic), and gas-exchange is not successful.
NIPCs after steroid-refractory hematopoietic stem-cell transplantation are said to be are highly lethal refractory diseases.

Acute graft-versus-host disease (GVHD) after hematopoietic stem-cell transplantation

Acute graft-versus-host disease (GVHD) is a serious post-transplant complication that determines the success or failure of a transplant. It occurs when lymphocytes from a donor after a hematopoietic stem cell transplant challenge the recipient's (patient’s) body as not self, resulting in excessive inflammation (cytokine storm).
GVHD that is resistant to steroid therapy, the standard first-line treatment, is said to be a complication that influences the prognosis of life after transplantation.

Acute respiratory distress syndrome (ARDS) associated with COVID-19

Acute respiratory distress syndrome (ARDS) is a severe respiratory failure syndrome due to various causes. ARDS may be caused by pneumonia, septicemia, or trauma. In the body, immune cells called neutrophils release enzymes into the blood that damage lung tissue such as the small air sacs (alveoli) and capillaries. This leads to fluid and protein in the blood passing through the blood vessels of the lungs and into the alveoli. As a result, fluid accumulates in the alveoli, causing severe respiratory failure.
New coronavirus infections (COVID-19) may also cause ARDS, which can lead to respiratory failure.

Business Activities

Our Business

Introducing our business that cords to patients’ future to a warmer world.

Development Pipeline

Introducing our development pipeline that is corded from an umbilical cord.